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Abstract
The success of liver transplantation has led to an ever-increasing demand for liver grafts. Since the first successful living donor liver
transplantation, this surgical innovation has been well established in children and has significantly relieved the crisis of donor organ shortage
for children. However, the extension of living donor liver transplantation to adult recipients is limited by the graft volume. The major concern
of adult-to-adult living donor liver transplantation is the adequate graft that can be harvested from a living donor. Small-for-size graft injury is
frequently observed. To develop novel effective treatments attenuating small-for-size liver graft injury during living donor liver
transplantation, it is important to explore the precise mechanism of acute phase small-for-size graft damage. Recently, a number of clinical
studies and animal experiments have been conducted to investigate the possible key issues on acute phase small-for-size liver graft injury,
such as mechanical injury from shear stress, subsequent inflammatory responses, and imbalance of vasoregulatory factors. This review
focuses on the mechanism of small-for-size liver graft injury based on the number of clinical and experimental studies. The latest research
findings of the significance of acute phase liver graft injury on late phase tumor recurrence and metastasis are also addressed.
© 2009 Published by Elsevier Inc. E
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1. Background
The emergence of adult-to-adult living donor liver
transplantation (ALDLT) over the last decade has led to a
dramatic increase in the number of liver grafts available. With
a continued shortage of cadaveric donor livers, ALDLT
currently offers a significant survival advantage to patients
listed for liver transplantation [1]. In single-center series,
candidates with potential living related donors are twice as
likely to undergo transplantation than those awaiting cadaveric
donor grafts, reducing waiting list mortality by half [2,3].
Furthermore, a liver graft from a living related donor allows
earlier intervention and lowers dropouts from disease
progression, leading to a higher life expectancy [4-6].
A major limitation of ALDLT is the size of the graft that
can be safely harvested from the living donor. In an adult
recipient, the liver graft from a living related donor is almost
always small-for-size. Owing to the reduced liver volume, a
small-for-size graft is less effective in coping with the portal
flow of an adult recipient. The shear stress from transient
portal hypertension causes acute phase mechanical injury [7-
9], which subsequently induces severe inflammatory⁎ Corresponding author. Tel.: +852 28199646; fax: +852 28199634.
E-mail address: kwanman@hkucc.hku.hk (K. Man).
0955-470X/$ – see front matter © 2009 Published by Elsevier Inc.
doi:10.1016/j.trre.2009.06.004Tresponses and then has a deleterious effect on the
posttransplantation outcome. In spite of rapid hepatic
regeneration, small-for-size liver grafts are associated with
worse graft function and survival [7-9]. More recently,
studies have reported an association between small-for-size
liver grafts and higher tumor recurrence after transplantation
for hepatocellular carcinoma (HCC) [10-12]. Despite its
limitations, the small-for-size graft remains the most
promising solution to the severe shortage of liver donors,
and the pursuit of its interests should be continued.
Recent evidence has shed new light on the under-
standing of small-for-size liver graft injury. This review
examines the pathogenesis of small-for-size liver graft
injury as well as its effect on graft and patient survival.
The recent link between small-for-size liver graft injury
and tumor recurrence after transplantation for HCC, albeit
controversial, will also be discussed.58
59
602. The issue of liver graft size
The size of a liver graft selected varies according to the
patient, the donor, and the transplant center [13]. In essence,
the choice is a delicate balance between donor safety and
recipient graft survival. However, as living donors are
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ARTICLE IN PRESShealthy, their survival is given precedence over graft efficacy
[14]. The normal liver has a large functional reserve. Starzl
et al [15] reported that a minimum residual liver volume of
30% was required for patient survival. Similar results were
reported by Shindl et al [16], where a residual liver volume
of less than 27% was associated with a marked increase in
the incidence of hepatic dysfunction. The ethical preference
for donor safety and a limit on the size of obtainable donor
liver mass explain why, with the exception of pediatric
patients, almost all partial liver grafts are suboptimal in size.
At the moment, the extended right liver graft technique
harvests the largest possible liver size (roughly 66% of the
donor liver) [17]. To obtain a graft of suitable size, ALDLT
often mandates the use of donor right hepatectomy. This
procedure has a donor safety profile much less favorable than
left hepatectomy, a large and potentially risky operation in its
own right. [18]. Donor morbidity and mortality are estimated
at 20% [19] and 0.5% [20], respectively, which have been
confirmed by a recent series [21].C
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3. Definition of the small-for-size graft
An accepted definition of the small-for-size graft has not
been established within the transplantation community.
There are currently 2 schools of thought.
Small-for-size liver grafts can be classified as those with
graft weight to estimated standard liver weight ratio of less
than 40% [22-24]. Grafts below the critical size are
associated with poor early graft function and a marked
reduction in graft and patient survival after transplantation
[13]. Alternatively, the definition of small-for-size liver
grafts can be extended to include all grafts smaller than the
standard liver volume (calculated using the formula by Urata
et al [25]) [26].
The former definition focuses on grafts with unacceptable
survival, whereas the latter classifies virtually all liver grafts
from living related donors as small-for-size [27]. Because of
the increasing evidence that size-related injury extends
beyond grafts less than 40% of the standard liver weight, the
latter definition is preferred because it represents a more
complete picture of the pathologic process. The cohort
described by the former will be referred to as marginal grafts.151
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162UN4. Small-for-size liver graft injury
Small-for-size liver graft injury refers to the insult related
to the small size of the graft in addition to ischemia/
reperfusion injury [27]. The initiating event is transient
portal hypertension after reperfusion due to graft size
mismatch [7,28]. High portal pressure causes mechanical
damage to the hepatic sinusoids (Fig. 1), which in turn leads
to tissue ischemia, imbalance of vasoregulatory factors,
increase in free radical formation, and exaggerated inflam-
matory response. The consequence of small-for-size liverTE
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graft injury is dependent on the extent of damage, which is
inversely proportional to the graft size. The possible
mechanism of small-for-size liver graft injury was summar-
ized in Fig. 2.
4.1. Transient portal hypertension
The liver has 2 major sites of vascular inflow: the portal
vein and the hepatic artery. Although portal blood flow
undergoes very little autoregulation within the liver, a
buffer system is in place to prevent excessive blood flow
from damaging the liver. An increase in portal pressure can
be countered by the hepatic arterial buffer response, where a
change in portal flow induces reciprocal effects on arterial
flow [29]. Through this buffer system, a liver can tolerate a
maximum of 20% increase in blood flow [30]. Such a buffer
system is present after transplantation [31] but is not enough
to compensate for the mismatched portal flow in small-for-
size grafts [32]. Because the portal flow destined for a
whole liver is directed through a partial liver, excessive
portal pressure is built up in small-for-size grafts, resulting
in portal hypertension. The increase in portal pressure due
to graft size mismatch is transient in nature and lasts for 30
minutes after reperfusion.
Shear stress from the transient portal hypertension
inflicts mechanical damage upon the hepatic sinusoidal
endothelium. Using a novel porcine liver transplantation
model, Kelly et al [33] demonstrated an inverse relationship
between the graft size and the extent of hepatic sinusoidal
injury. The presence of severe sinusoidal injury was
reported in grafts with an estimated standard liver volume
(ESLV) of 20% or less. The damage was less severe in
grafts with an ESLV of 30% and was further lessened in
grafts with an ESLV of 60%. Damage was virtually
nonexistent in whole grafts [28].
4.2. Severer ischemia injury
Being the principle vessels involved in transvascular
exchange between the blood and the liver parenchymal cells,
the sinusoids are critical in the maintenance of hepatic
functions [28]. A healthy microcirculatory environment is
vital to the recovery of graft function after reperfusion
[34,35]. Injury to the sinusoidal cells results in sinusoidal
stasis and congestion [36], and a lack of functional
microcirculation exposes the liver tissue to ischemia [37].
Although the hemodynamic changes are transient, tissue
ischemia secondary to sinusoidal insult causes progressive
cellular damage. The histologic hallmarks of prolonged
ischemia include swelling of mitochondria and hepatocytes
as well as presence of apoptosis [28].
4.3. Imbalance of vasoregulatory peptides
In the normal liver, the maintenance of hepatic micro-
circulation relies heavily on the delicate balance of vasocon-
striction and vasodilatation. Prolonged ischemia from
sinusoidal damage tips the balance in favor of vasoconstriction
CT
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Fig. 1. Hepatic ultrastructural changes after liver transplantation in animal (A) and human (B) studies. A, Tremendous mitochondrial swelling with unvisualized
cristae (*) was found in the hepatocytes. Collapse of the Disse space (arrow) and an irregular large gap (arrow head) between the sinusoidal lining cells also
occurred. Total disruption of hepatic sinusoidal lining cells (arrows) was presented at 24 hours after reperfusion in animal study (animal study from Man et al
[28]; human study from Man et al [7]).
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ARTICLE IN PRESSE[7]. The gene for endothelin 1 is overexpressed as a result of
ischemia, resulting in its overproduction [38]. Endothelin 1 is
the most potent constrictor peptide of vascular smooth muscleUN
CO
RR
Fig. 2. Pathways to small-for[39] and increases intrahepatic resistance by directly constrict-
ing the remaining hepatic sinusoids. On the other hand, the
gene for endothelial nitric oxide synthase is underexpressed.-size liver graft injury.
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Endothelial nitric oxide synthase is involved in the main-
tenance of vasodilatation through the production of endogen-
ous nitric oxide [40]. Endogenous nitric oxide in turn is vital in
the physiological regulation of blood flow [41]. This results in
a further shift of balance toward vasoconstriction.
Furthermore, genes for heat shock protein 70 and heme
oxygenase 1, which are important for tissue repair [42] and
protection against vascular constriction [43], respectively,
are also underexpressed in small-for-size grafts. A shift
toward vasoconstriction results in further ischemic damage.
4.4. Increase in free radical formation
The production of free radicals is markedly increased in
small-for-size grafts shortly after reperfusion [44]. Zhong et al
[44] suggested 2 possible mechanisms of free radical
formation in small-for-size grafts. First, a reduction in graft
size increases the metabolic burden on the graft. As
metabolism increases, mitochondria produce more oxygen
radicals. At the same time, reduced glutathione, a potent
antioxidant, is consumed more rapidly in smaller grafts. The
result is a net increase in free radicals and more severe graft
injury [45]. A second explanation involves Kupffer cells. Each
individual Kupffer cell in a small-for-size graft is exposed to
higher amounts of endotoxin than that in a whole liver graft
[46]. In turn, the exposure to endotoxin triggers Kupffer cells
to release a large quantity of free radicals. Regardless of the
method of release, the free radicals cause direct oxidative
damage to the remaining hepatocytes and sinusoids. An
increase in free radical formation is associated with increased
graft injury andworse graft function, as indicated by increased
serum alanine transferase and bilirubin levels as well as
histologic signs of necrosis and leukocyte infiltration.
4.5. Exaggerated inflammatory response
A common finding in liver grafts after transplantation is a
cellular infiltrate secondary to ischemia/reperfusion injury.
The cellular infiltrate predominantly consists of macro-
phages. As a result of transient portal hypertension, the
macrophage cell number and activity are substantially
increased in small-for-size grafts. Using a rat liver
transplantation model, Yang et al [47] demonstrated a
significantly higher macrophage infiltrate in the periportal
area of small-for-size grafts compared with that of whole
grafts during early phase after reperfusion. The number of
macrophages expanded to reach a peak at 72 hours after
reperfusion. In addition to an increase in the cell number, the
activity of the macrophages was also enhanced in small-for-
size liver grafts. This was represented by exaggerated
expression of inducible nitric oxide synthase by the
macrophages in small-for-size grafts.
The invading macrophages in small-for-size grafts secrete
high levels of cytokines, specifically interleukin 1β and
interleukin 2, during early phase after reperfusion. In the in
vitro setting, Yang et al [47] demonstrated that interleukin 1β
transforms macrophages into antigen-presenting cells, asOO
F
evidenced by the expression of CD80 and CD86. These 2
molecules provide vital stimuli to prime T cells against
antigens presented by antigen-presenting cells. The presence
of a larger number of antigen-presenting cells in small-for-
size grafts enhances alloantigen recognition and subse-
quently results in accelerated graft rejection.
In a separate study by Yang et al [48], vascular endothelial
growth factor (VEGF) was put forward as the vital link
between transient portal hypertension and macrophage
activation in small-for-size grafts. Microcirculatory injury
after reperfusion triggers VEGF secretion from hepatocytes,
a vital physiological process needed for rapid hepatic
regeneration. However, VEGF is also an important mediator
of monocyte and activities, and excessive VEGF is produced
in small-for-size grafts because of more profound micro-
circulatory damage. Subsequently, an increase in production
of intragraft VEGF results in the enhancement of migratory
activities of monocytes in small-for-size grafts [48].TE
D
P5. Clinical consequence of small-for-size livergraft injury
The most severe consequence of small-for-size liver graft
injury is small-for-size syndrome, defined as graft dysfunc-
tion or graft failure during the first postoperative week after
the exclusion of other causes [49]. This syndrome is almost
exclusive to marginal grafts. Several notable studies have
reported different cutoff points for marginal grafts. Kawa-
saki et al [50] set the limit of safe liver graft size at 30% of
ESLV. This threshold point is shared by Nishizaki et al [51].
Lo et al [52] reported that graft sizes below 40% of ESLV
have low success rates. Lee et al [72] used a graft-recipient
weight ratio (GRWR) of less than 0.8% as the limit, whereas
Ben-Haim et al [53] reported that a GRWR as low as 0.6%
is suitable for patients with less severe end-stage liver
disease. It is important to note, however, that these limits are
mainly arbitrary.
Small-for-size syndrome is attributable solely to size of the
graft because not every marginal graft results in dysfunction
or failure. Small-for-size syndrome is a multifactorial disease.
Other factors involved in small-for-size syndrome include
graft-related causes (a lack of liver regeneration [54], high
portal inflow [55], low venous outflow [56], preexisting
steatosis in the donor [57]), and recipient-related causes
(severe preoperative end-stage liver disease [53], presence of
cirrhosis [58], and poor preoperative health status).
For small-for-size liver grafts with GRWR of more than
0.8%, a difference in survival compared with whole liver
grafts is less convincing. Earlier reports on short-term
survival after liver transplantation suggested poorer graft
survival in ALDLT recipients. Using the United Network for
Organ Sharing data in a retrospective analysis, Abt et al [8]
discovered a significantly higher rate of allograft failure in
ALDLT recipients compared with deceased donor liver
transplantation (DDLT) recipients (hazards ratio, 1.66;
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ARTICLE IN PRESSconfidence interval, 1.30–2.11). With the same database,
Thuluvath and Yoo [9] reported a 2-year graft survival of
64.4% in ALDLT recipients compared with 73.3% in the
DDLT recipients. The difference in graft survival between
the 2 groups was statistically significant. However, because
of the availability of retransplantation for recipients who
developed allograft failure, patient survival after ALDLT
remained similar to that of DDLT. A crucial limitation of the
United Network for Organ Sharing database is omission of
data on graft size. It is impossible to confirm whether size
plays a role in the poorer graft survival.
A more recent study on long-term survival after liver
transplantation refutes previous evidence of poorer survival
in ALDLT recipients. Maluf et al [59] found no statistical
differences between ALDLTand DDLT in the patient or graft
survival rates at 5 years after transplantation. A possible
reason for the discrepancy in results is an improvement of
surgical technique at a high volume center. Results from our
center also demonstrated a lack of significant difference in
patient and graft survival between the 2 groups. With a
median follow-up time of 27 months, the graft and patient
survival rates were 88% and 90%, respectively, in the
ALDLT group, whereas the survival rates were both 84% in
the DDLT group. In this study, the ALDLT grafts had a
significantly lower median graft weight to estimated
standard liver weight ratio (48.9% vs 98.2%). Liu et al
[46] cited that their regular inclusion of the middle hepatic
vein in partial liver grafts, which allows good venous
drainage to meet the high metabolic demand of recipients,
might have resulted in the more favorable survival outcomes
in ALDLT.356
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6. Small-for-size liver graft injury on late phase
tumor recurrence
6.1. Background
Although ALDLT confers a substantial survival advan-
tage for patients with HCC awaiting transplantation, the
preference of ALDLT to DDLT is based primarily on
hypothetical studies using decision analysis models [4,5].
Such studies assume comparable tumor recurrence rates and
patient survival after ALDLT and DDLT. With the adoption
of the Milan criteria, DDLT offers a tumor recurrence rate of
less than 10% [60]. This in turn confers a patient survival rate
comparable to patients undergoing DDLT without HCC
(75% survival at 4 years) [61,62]. In comparison, the tumor
recurrence rate after ALDLT remains controversial.374
375
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3806.2. Clinical evidence of inferior oncologic outcome
Recently, a number of centers have compared the
outcomes of ALDLT and DDLT using retrospective clinical
data. The inability to conduct a randomized controlled trial
has led to conflicting results in different centers. However,TE
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there is increasing evidence that partial liver grafts lead to
higher tumor recurrence after ALDLT for HCC.
On one hand, Hwang et al [63] reported no significant
difference in the HCC recurrence rates between the 2 cohorts.
Instead, tumor size, grossmajor vessel invasion, and histologic
differentiation were cited as the major risk factors for tumor
recurrence. Gondolesi et al [64] also observed comparable
tumor recurrence rates between ALDLT and DDLT.
On the other hand, an increasing amount of evidence
points to a higher tumor recurrence rate after transplantation
using ALDLT. In 2004, Kulik et al [12] reported higher HCC
tumor recurrence rates in the “fast tracked” ALDLT cohort
(22%) compared with the DDLT cohort (3%). They reasoned
that the shorter waiting time did not allow an adequate period
to assess the tumor's biological behavior. Hence, the ALDLT
group included more aggressive tumors, which may have
accounted for the higher tumor recurrence rate. However, the
team also hypothesized that, by virtue of its relatively small
size, the liver graft from a living donor could potentially
promote tumor growth and metastasis independently and,
thus, result in a higher tumor recurrence rate. This theory has
become the focus of more recent studies on the topic.
In 2007, Lo et al [11] reported a 5-year recurrence rate of
22% in the ALDLT cohort and a 5-year recurrence rate of 0%
in the DDLT cohort. In the study, tumor recurrence was the
major cause of death after transplantation, with 6 of the 10
deaths attributable to tumor recurrence [11]. Furthermore, the
5-year patient survival rate was substantially lower in the
ALDLT cohort (58% vs 94%), which, however, without
statistical significance, was most likely because of the small
sample size. In the same year, the multicenter Adult-to-Adult
Living Donor Liver Transplantation Cohort Study reported a
3-year higher tumor recurrence rate in the ALDLT cohort
(29% vs 0%) [10]. This time, however, there was little
difference in the overall patient survival of the 2 groups. A
striking similarity in the 2 studies was the lack of tumor
recurrence in the DDLT cohort. The finding that even
transplantation for tumors outside the Milan and University
of California, San Francisco, criteria lacked recurrence
suggested that factors other than tumor aggressiveness before
transplantation were responsible for the findings. Again, both
studies proposed that the small size of the living donor liver
graft was potentially responsible for the higher recurrence
rate. However, the hypothesis yet remains unproven.
Most recently, Hwang et al [65] tested the effect of
GRWR on tumor recurrence with a retrospective study on
past transplantations. The study found no statistical differ-
ences in the overall patient survival (P = .105) and
recurrence-free survival (P = .406) among grafts with
GRWR less than .8 (small grafts), GRWR of .8–1.0 (mid
sized), GRWR greater than 1.0 (large sized), and those with
GRWR greater than 1.5 (whole grafts). However, because of
a high amount of sample stratification, the sample size of
each group and, hence, the power were not large enough to
detect a statistical difference. Table 1 shows the results of the
aforementioned studies. In the face of such controversy, an
381
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Table 1t1:1
Tumor recurrence after liver transplantation using DDLT and LDLTt1:2
t1:3 Author Sample size Date Tumor recurrence rate Patient survival rate
t1:4 LDLT vs DDLT DDLT LDLT P DDLT LDLT P
t1:5 Kulik 41 vs 33 2004 0%/9 mo 15%/8 mo .044 – – –
t1:6 Gondolesi 36 vs 165 2004 83%/2 yrs 74%/2 y .300 70%/2 y 60%/2 y .200
t1:7 Hwang 237 vs 75 2005 82%/2 y 79.7%/2 y .884 61%/3 y 73%/3 y .043
t1:8 Lo 43 vs 17 2007 0%/5 y 29%/5 y .029 94%/5 y 58%/5 y .187
t1:9 Fisher 58 vs 34 2007 0%/3 y 29%/y Q2.002 63%/3 y 67%/3 y .910
Q3
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is necessary.
6.3. Molecular pathways linking small-for-size liver graft
injury to tumor recurrence after transplantation for HCC
Crucially, there is an overlap of processes in small-for-
size graft injury with those involved in tumor invasion. SuchUN
CO
RR
EC
Fig. 3. A, Liver tumor development after liver transplantation using whole or small-
compared at different time points. C, Liver tumor growth in nude mice at week 4 and
tumors from nude mice was also compared. *P b .05 group W vs group S. (FromOO
Ffactors may provide a favorable environment for tumor
recurrence in small-for-size grafts.
The main pathway in which the outgrowth of preexisting
micrometastases can be promoted in small-for-size grafts is
through tissue ischemia. It is present in small-for-size grafts
secondary to portal hyperperfusion injury. The ischemia is
exacerbated by the hepatic arterial buffer response because it
leads to a decrease in hepatic arterial flow. In a study by DoiTE
D
PR
for-size liver grafts at day 14 and day 21. B, The liver occupied by tumor was
week 6 after tumor implantation from groupWor group S. D, The volume of
Man et al., Ann Surg, in press).
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ARTICLE IN PRESSet al [66], prolonged liver ischemia induced higher secretion
of inflammatory cytokines, increased free radical formation,
and subsequently increased liver metastasis of colon cancer.
van der Bilt et al [67] reported that ischemic lobes in murine
livers had a 5-fold to 6-fold increase in outgrowth of
micrometastases compared with nonischemic lobes. The
same study also discovered that a decrease in ischemic time
would drastically decrease the incidence of metastasis.
6.4. Liver graft injury and tumor recurrence
Recently, we have demonstrated the significance of
surgical stress on tumor behavior in a rat liver tumor model
undergoing ischemia/reperfusion injury and major hepa-
tectomy. The surgical stress resulting from hepatic
ischemia/reperfusion injury and/or major hepatectomy did
not only make the hepatic microenvironment (“soil”)
favorable for tumor cell growth, migration, and invasion
through stimulation of acute phase inflammatory response
and disturbance of microcirculatory barrier function but
also made the tumor cells (“seeds”) more aggressive for
local and distant metastases by directly activating cell
migration and invasion pathways in the tumor cell itself
[68]. We also demonstrated the significance of graft size in
tumor growth and invasiveness after liver transplantation in
a rat model. More rapid and invasive tumor development in
small-for-size liver grafts was evident in morphological
examination and was supported by the signaling linking to
angiogenesis and tumor invasiveness. We further confirmed
the invasiveness of tumors developed from small-for-size
grafts in a novel orthotopic nude mice implantation model
(Fig. 3) [69]. It was found that acute phase small-for-sizeUN
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Fig. 4. Possible mechanism of invasive tumor growthTE
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liver graft injury does not only provide a microenvironment
that favors tumor development but also promotes the
invasiveness of tumor cells.
The small liver remnants and small-for-size liver graft
expressed significantly high levels of early overexpression of
early growth response 1, focal adhesion kinase, and VEGF
[68,69]. Early growth response 1 switches on several
cascades of inflammatory response as well as angiogenesis
and cell adhesion [70]. The activation of focal adhesion
kinase is related to microvascular barrier dysfunction and has
been demonstrated to promote an invasive tumor cell
phenotype [71]. Vascular endothelial growth factor is a
major promoter of angiogenesis [72].
From the studies, there are several possible mechanisms
in which small-for-size liver graft injury can increase the
incidence of tumor recurrence. They may include increase in
cell adhesion factors, liver parenchyma damage/microvas-
cular barrier dysfunction, and angiogenesis.
6.5. Cell adhesion
Prolonged ischemia is associated with higher expression
of E-selectin and, consequently, a higher incidence of tumor
metastasis [73]. E-selectin is a molecule that is important in
inflammatory responses [74] because it facilitates the
adhesion of leukocytes to endothelial cells [75]. It is also
reportedly involved in liver cancer growth and metastasis
[76] by facilitating the adhesion of cancer cells to the
endothelium [77]. Expression of E-selectin increases with the
length of ischemic period. This is because E-selectin is up-
regulated by tumor necrosis factor α and interleukin 1 [78],
whose expression is in turn promoted by liver ischemiaafter transplantation using small-for-size grafts.
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[79]. It is also possible that other adhesion molecules
expressed during ischemia may have similar effects on
tumor recurrence.
6.6. Microvascular dysfunction
Apoptosis is the most important mechanism of ischemia-
induced cell death and was shown by van der Bilt et al [67] to
be also important in tumor metastasis. Liver ischemic injury
induces areas of apoptosis, resulting in infiltration of
lymphocytes into the area. Areas of necrosis then develop
in the liver parenchyma. This facilitates the growth of tumor
cells [67] as they preferentially invade into zones surround-
ing tissue necrosis.
6.7. Angiogenesis
Vascular endothelial growth factor, as mentioned
previously, is a major angiogenic factor and is up-regulated
by tissue hypoxia secondary to microvascular dysfunction.
Previous studies demonstrated the ability of VEGF to
induce angiogenesis in cerebral ischemia [72]. Vascular
endothelial growth factor was also reported to be important
in ischemic wound healing [80]. A crucial study discovered
a direct correlation between vascular clamping time and
intrahepatic VEGF levels [81], which led to a less favorable
oncologic outcome in these patients. As Yang et al [48]
reported an increase in VEGF expression in small-for-size
grafts, it is possible that small-for-size graft injury-induced
ischemia may result in VEGF overexpression and, conse-
quently, angiogenesis.
In summary, although partial liver grafts provide earlier
transplantation and lowers waiting list mortality, the major
concern is posttransplantation survival. Small-for-size liver
graft injury is virtually present in all partial liver grafts. It is a
multistep detrimental process reinforced by strong collat-
erals. The process begins with transient portal hypertension
due to graft size mismatch, which inflicts mechanical
damage on the hepatic sinusoidal endothelium. Dysfunction
of the hepatic sinusoidal endothelium results in global
ischemia to the liver graft, which triggers a cascade of
vasoconstriction, free radical production, and monocyte
migration to the liver graft. The consequence is acute phase
graft injury. The extent of damage and graft dysfunction is
dependent on the size of the partial liver graft. Clinical
studies have, however, demonstrated that with good surgical
technique and the use of grafts with graft weight to estimated
standard liver weight ratio greater than 40%, acute graft
failure can be minimized to levels comparable with whole
liver grafts. Further evidence though is needed for
comparison of the long-term outcome (N5 years).560
561
562
563
564
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5667. Conclusions
Acute phase small-for-size graft injury may not only
affect short-term graft survival but may also contribute to latephase tumor recurrence and metastasis in liver transplanta-
tion for liver cancer (Fig. 4). An improved understanding of
small-for-size liver graft injury will facilitate preventive and
therapeutic measures not only for early graft dysfunction but
also for late phase tumor recurrence and metastasis.TE
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